Rheumatoid Arthritis (RA) Treatments

Find Rheumatoid Arthritis (RA) Treatments

Generic Name

Infliximab

Brand Names

Avsola, Inflectra, Remicade, Renflexis, Zymfentra

FDA approval date: August 24, 1998

Classification: Tumor Necrosis Factor Blocker

Form: Injection, Kit

What is Avsola (Infliximab)?

AVSOLA is a tumor necrosis factor blocker indicated for: Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Treatment of Rheumatoid Arthritis With Disease-modifying Antirheumatic Drugs (DMARDs): Predictors of Response

Who is this study for: Patients with early rheumatoid arthritis

Enrollment Status: Recruiting

Publish Date: June 17, 2026

Intervention Type: Drug

Study Drug: Methotrexate

Study Phase: Phase 3

Summary: Rheumatoid arthritis (RA) is a common disease with approximately 1% prevalence. RA is also a chronic, progressive disease with no cure. Current treatment goals are to minimize pain, limit joint damage, and prevent loss of function. Drugs used to treat RA include non-steroidal anti-inflammatory drugs (NSAIDS), glucocorticoids, and disease-modifying anti-rheumatic drugs (DMARDs), including biologics...

Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms

Who is this study for: Adult patients with stroke, aneurysm, vasculitis, and tumor necrosis factor-alpha

Enrollment Status: Recruiting

Publish Date: June 11, 2026

Intervention Type: Drug

Study Drug: Infliximab

Study Phase: Phase 1/Phase 2

Summary: Patients harboring dolichoectactic vertebrobasilar (DVB) aneurysms are at risk of suffering SAH, ischemic stroke, and/or brainstem compression and many patients are not offered invasive treatment due to the futility of existing surgical methods. Consequently, there is demand for development of medical therapy for DVB aneurysms

A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis

Enrollment Status: Recruiting

Publish Date: June 10, 2026

Intervention Type: Drug

Study Phase: Phase 2

Summary: Immune-related colitis from immune checkpoint inhibitors (ICI) is a common adverse effect causing significant morbidity and impairment of quality of life (QoL). Steroids are the first line of treatment for severe ICI induced Immune- mediated diarrhea and colitis (IMDC). If there is no improvement in 48 to 72 hours, other immunosuppressive agents (infliximab, vedolizumab) are recommended. However, ...

View All Clinical Trials

Related Latest Advances

Treatment Approaches for Posterior Uveitis in Ocular Sarcoidosis: A Narrative Review.

Journal: Seminars in ophthalmology

Published: June 23, 2026

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

Journal: The Cochrane database of systematic reviews

Published: June 23, 2026

A Pediatric Case of Blau Syndrome with NOD2 p.Arg587Cys Mutation Successfully Managed with Infliximab: A Long-Term Follow-Up Study.

Journal: Ocular immunology and inflammation

Published: June 14, 2026

View All Latest Advances

Brand Information

AVSOLA (infliximab-axxq)

1DOSAGE FORMS AND STRENGTHS

For injection: 100 mg of infliximab-axxq as a white to slightly yellow lyophilized powder in a single-dose vial for reconstitution and dilution.

2CONTRAINDICATIONS

The use of AVSOLA at doses >5 mg/kg is contraindicated in patients with moderate or severe heart failure

AVSOLA is contraindicated in patients with a previous severe hypersensitivity reaction to infliximab products or any of the inactive ingredients of AVSOLA or any murine proteins [severe hypersensitivity reactions have included anaphylaxis, hypotension, and serum sickness]

3OVERDOSAGE

Single doses up to 20 mg/kg have been administered without any direct toxic effect. In case of overdosage, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions or effects

4DESCRIPTION

Infliximab-axxq, a tumor necrosis factor (TNF) blocker, is a chimeric IgG1κ monoclonal antibody (composed of human constant and murine variable regions). It has a molecular weight of approximately 149.1 kilodaltons. Infliximab-axxq is produced in a recombinant Chinese Hamster Ovary (CHO) cell line.

AVSOLA (infliximab-axxq) for injection is supplied as a sterile, preservative-free, white to slightly yellow, lyophilized powder for intravenous infusion after reconstitution and dilution. Following reconstitution with 10 mL of Sterile Water for Injection, USP, the final concentration is 10 mg/mL and the resulting pH is approximately 7.2. Each single-dose vial contains 100 mg infliximab-axxq, dibasic sodium phosphate, anhydrous (4.9 mg), monobasic sodium phosphate, monohydrate (2.2 mg), polysorbate 80 (0.5 mg), and sucrose (500 mg).

5REFERENCES

Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: A prospective multicenter study.

6PATIENT COUNSELING INFORMATION

Advise the patient or their caregiver to read the FDA-approved patient labeling (Medication Guide).

Patients or their caregivers should be advised of the potential benefits and risks of AVSOLA. Healthcare providers should instruct their patients or their caregivers to read the Medication Guide before starting AVSOLA therapy and to reread it each time they receive an infusion.

7PRINCIPAL DISPLAY PANEL - 100 mg Vial Carton Label

100

AMGEN

NDC 55513-670-01

AVSOLA

100 mg/vial

For Intravenous infusion only

Single-Dose Vial. Discard unused portion.

Contents: Each carton contains one 100 mg AVSOLA Single-Dose Vial.

Rx Only

PRINCIPAL DISPLAY PANEL - 100 mg Vial Carton Label